Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum ABSWOBY +4.56%67 Cash-to-Debt is 0.06 as of Jun. 2026, which is 14% below its 10-year median of 0.07. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $18.51 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 983 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 90.03% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Swedish Orphan Biovitrum AB's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.06.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Swedish Orphan Biovitrum ABcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's Cash-to-Debt or its related term are showing as below:
SWOBY'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.07 Max: 749.75
Current: 0.06
During the past 13 years, Swedish Orphan Biovitrum AB's highest Cash to Debt Ratio was 749.75. The lowest was 0.01. And the median was 0.07.
SWOBY's Cash-to-Debt is ranked worse than 90.03% of 983
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs SWOBY: 0.06
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Swedish Orphan Biovitrum AB Cash-to-Debt Related Terms
Swedish Orphan Biovitrum AB Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (SWOBY) has a Cash-to-Debt of 0.06 as of Jun. 2026. This is 14% below median its historical median of 0.07. Over the past decade, Swedish Orphan Biovitrum AB's Cash-to-Debt has ranged from 0.01 to 749.75. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #885 out of 983 companies in the Drug Manufacturers industry, placing it in the top 90%.
Is Swedish Orphan Biovitrum AB's Cash-to-Debt too high?
Swedish Orphan Biovitrum AB's current Cash-to-Debt of 0.06 is 14% below median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 749.75. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Swedish Orphan Biovitrum AB's value of 0.06 is 93.9% below this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #885 out of 983 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #885 out of 983 companies for Cash-to-Debt. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median Cash-to-Debt is 0.98. Swedish Orphan Biovitrum AB's value of 0.06 is 93.9% below this benchmark. Historically, Swedish Orphan Biovitrum AB's own Cash-to-Debt has ranged from 0.01 to 749.75 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 0.98, Swedish Orphan Biovitrum AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Cash-to-Debt of 0.06 is 93.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Cash-to-Debt is 0.06, which is 14% below median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.51, compared to a current price of $24.31 — trading 31.3% above its estimated fair value. The current Cash-to-Debt is 0.06, which is 14% below median its 10-year median of 0.07 and 93.9% below the Drug Manufacturers industry median of 0.98. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Cash-to-Debt is 0.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $24.31 is trading 31.3% above its estimated GF Value™ of $18.51.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
Cash-to-Debt: 0.06 (14% below median its 10-year median of 0.07)
GF Value™: $18.51 vs. price of $24.31 (31.3% above fair value)
Industry Position: 93.9% below the Drug Manufacturers median (#885 of 983)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
